Sarcoidosis Research and Clinical Trials
Researchers at Mount Sinai and worldwide have been working for more than 80 years to determine the cause of sarcoidosis in order to build the foundation for a cure. Mount Sinai is an NIH Center of Excellence for research in sarcoidosis, and our Sarcoidosis Program is actively investigating areas such as pulmonary hypertension in sarcoidosis and antibody mediated treatment of sarcoidosis. We are also exploring the biology of the disease in order to increase our understanding of how the condition itself develops and advances.
Among Mount Sinai scientists’ investigative activities are several clinical trials, which offer patients access to advanced diagnostic tests and treatment options. Our current clinical trials include the following:
- KIACTA (TM) for the treamtent of sarcoidosis. This study seeks to evaluate the safety and efficacy of KIACTA (TM) in the treatment of medical manifestations of sarcoidosis.
- Pirfenodone for the treatment of idiopathic pulmonary fibrosis (IPF). This study seeks to evaluate the efficacy of Pirfenidone, which has demonstrated antifibrotic and anti-inflammatory properties, in the management of IPF.